GNE-3500

Name: GNE-3500
Brand: MedChemExpress
SKU: HY-16983
Rating: 4.5 (1 reviews)

Cat. No.: HY-16983 Purity: 98.90%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

GNE-3500 is a selective, orally active antagonist for Retinoic Acid Receptor-Related Orphan Receptor C (RORc, also known as RORγ or NR1F3) with an EC₅₀ of 12 nM. GNE-3500 exhibits good pharmacokinetic characteristics in rats.

For research use only. We do not sell to patients.

GNE-3500 Chemical Structure

CAS No. : 1537859-24-7

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ROR Isoform Specific Products:

View All Isoforms

RORγ RORα RORβ

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

ROR-γ

12 nM (EC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	EC₅₀	0.047 μM Compound: 2	Inverse agonist activity at GAL4-fused human RORc expressed in HEK293 cells assessed as activation of basal transcriptional activity by dual-glo luciferase reporter gene assay Inverse agonist activity at GAL4-fused human RORc expressed in HEK293 cells assessed as activation of basal transcriptional activity by dual-glo luciferase reporter gene assay	[PMID: 27524313]
HEK293	EC₅₀	5.4 μM Compound: 2	Inverse agonist activity at GAL4-fused human RORa expressed in HEK293 cells assessed as activation of basal transcriptional activity by dual-glo luciferase reporter gene assay Inverse agonist activity at GAL4-fused human RORa expressed in HEK293 cells assessed as activation of basal transcriptional activity by dual-glo luciferase reporter gene assay	[PMID: 27524313]
HEK293	EC₅₀	5.4 μM Compound: 2	Inverse agonist activity at GAL4-fused human RORb expressed in HEK293 cells assessed as activation of basal transcriptional activity by dual-glo luciferase reporter gene assay Inverse agonist activity at GAL4-fused human RORb expressed in HEK293 cells assessed as activation of basal transcriptional activity by dual-glo luciferase reporter gene assay	[PMID: 27524313]
PBMC	EC₅₀	0.45 μM Compound: 2	Inhibition of IL-17AA production in anti-CD3 and anti-CD28 stimulated human PBMC measured after 1 hr by Sandwich ELISA Inhibition of IL-17AA production in anti-CD3 and anti-CD28 stimulated human PBMC measured after 1 hr by Sandwich ELISA	[PMID: 27524313]
PBMC	EC₅₀	> 20 μM Compound: 2	Cytotoxicity against human PBMC assessed as cell viability measured after 48 hrs by CellTiter-Glo assay Cytotoxicity against human PBMC assessed as cell viability measured after 48 hrs by CellTiter-Glo assay	[PMID: 27524313]
PBMC	EC₅₀	> 20 μM Compound: 2	Inhibition of IFN-gamma production in anti-CD3 and anti-CD28 stimulated human PBMC measured after 1 hr by Sandwich ELISA Inhibition of IFN-gamma production in anti-CD3 and anti-CD28 stimulated human PBMC measured after 1 hr by Sandwich ELISA	[PMID: 27524313]

Molecular Weight

459.58

Formula

C₂₄H₃₀FN₃O₃S

CAS No.

1537859-24-7

Appearance

Solid

Color

White to off-white

SMILES

FC1=CC(N2CCN(C(C)=O)CC2)=CC=C1CN3[C@@H](C)CC[C@H](C4=CC=CC=C4)S3(=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (108.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1759 mL	10.8795 mL	21.7590 mL
5 mM	0.4352 mL	2.1759 mL	4.3518 mL
10 mM	0.2176 mL	1.0879 mL	2.1759 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.72 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.72 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 1.25 mg/mL (2.72 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.90%

Select Batch:

Data Sheet (272 KB) SDS (393 KB)

COA (248 KB) HNMR (121 KB) LCMS (135 KB)

Handling Instructions (2659 KB)

References

[1]. Fauber BP, et al., Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist. J Med Chem. 2015 Jul 9;58(13):5308-22. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1759 mL	10.8795 mL	21.7590 mL	54.3975 mL
	5 mM	0.4352 mL	2.1759 mL	4.3518 mL	10.8795 mL
	10 mM	0.2176 mL	1.0879 mL	2.1759 mL	5.4397 mL
	15 mM	0.1451 mL	0.7253 mL	1.4506 mL	3.6265 mL
	20 mM	0.1088 mL	0.5440 mL	1.0879 mL	2.7199 mL
	25 mM	0.0870 mL	0.4352 mL	0.8704 mL	2.1759 mL
	30 mM	0.0725 mL	0.3626 mL	0.7253 mL	1.8132 mL
	40 mM	0.0544 mL	0.2720 mL	0.5440 mL	1.3599 mL
	50 mM	0.0435 mL	0.2176 mL	0.4352 mL	1.0879 mL
	60 mM	0.0363 mL	0.1813 mL	0.3626 mL	0.9066 mL
	80 mM	0.0272 mL	0.1360 mL	0.2720 mL	0.6800 mL
	100 mM	0.0218 mL	0.1088 mL	0.2176 mL	0.5440 mL

GNE-3500 Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GNE-35001537859-24-7GNE3500GNE 3500RORRAR-related orphan receptorpsoriasisrheumatoid arthritisselectiveorally activeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

GNE-3500

Customer Review

GNE-3500 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ROR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

GNE-3500 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report